The completion of the £2 billion buyback removes a known capital return catalyst. Monitor GSK's next capital allocation announcement for any new buyback or dividend policy. No immediate trading action warranted.
GSK drugs
GSK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 29 $52.81entry
- T+1 · 5mo ago −0.74%α −1.52% · $52.42
- T+5 · 4mo ago +0.53%α −0.86% · $53.09
- T+20 · 4mo ago −2.76%α −2.49% · $51.35
- T+60 · 8w ago −3.96%α −8.33% · $50.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK completed its £2 billion share buyback program, purchasing 123,939,156 ordinary shares since February 24, 2025. The final tranche of 1,054,653 shares was bought between June 22-26, 2026, at an average price of approximately 1,953.54 GBp per share. This is a routine capital return milestone with no new financial data or strategic changes.
Key Facts
- GSK completed its £2 billion buyback program announced on February 24, 2025.
- Since February 24, 2025, GSK purchased 123,939,156 ordinary shares for aggregate consideration of just under £2 billion.
- The final week (June 22-26, 2026) saw purchases of 1,054,653 shares at volume-weighted average prices between 1,919.89 GBp and 1,967.46 GBp.
- Following purchases, GSK holds 270,881,064 shares in treasury and has 4,045,395,364 shares in issue (excluding treasury).
- Treasury shares represent 6.70% of total voting rights.
Financial Impact
£2 billion total buyback completed; no new financial data or guidance provided.
Risk Factors
- No new buyback program announced; capital return to shareholders may pause.
- Treasury shares at 6.70% could be reissued for acquisitions or employee compensation, potentially diluting future EPS.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006273 |
| Document: 0001654954-26-006273-index-headers.html | 0001654954-26-006273 |
| Document: 0001654954-26-006273-index.html | 0001654954-26-006273 |
| Document: 0001654954-26-006273.txt | 0001654954-26-006273 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers